(CYCC) Cyclacel Pharmaceuticals - Ratings and Ratios

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) is a clinical-stage biopharmaceutical company specializing in the development of innovative cancer therapies. The companys pipeline focuses on addressing unmet medical needs in oncology, with a particular emphasis on hematological malignancies and solid tumors. Its lead candidate, fadraciclib, is a CDK inhibitor currently in Phase 1/2 clinical trials for solid tumors and hematological malignancies. The compound is also being evaluated in combination with venetoclax for relapsed or refractory chronic lymphocytic leukemia (CLL). Additionally, Cyclacel is advancing plogosertib, a polo-like kinase inhibitor, in Phase 1/2 trials for advanced solid tumors and hematological malignancies.

Cyclacel has established a clinical collaboration with the University of Texas MD Anderson Cancer Center to evaluate the safety and efficacy of its compounds in patients with hematological malignancies, including CLL, acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and other leukemias. This partnership underscores the companys commitment to leveraging academic and clinical expertise to accelerate the development of its pipeline. Founded in 1996, Cyclacel Pharmaceuticals is headquartered in Berkeley Heights, New Jersey, with operations in the United States, the United Kingdom, and internationally.

### 3-Month Forecast Technical Outlook: - The stock is trading below its SMA20 ($0.33) and SMA50 ($0.35), indicating near-term weakness. - The SMA200 ($0.96) is significantly above the current price, suggesting long-term downside momentum. - ATR ($0.04) indicates low volatility, signaling potential range-bound trading in the near term. Fundamental Outlook: - Market cap of $65.47M reflects its micro-cap status, with limited liquidity. - The P/B ratio of 2.02 suggests the stock is trading at a premium to its book value. - The absence of P/E and forward P/E ratios highlights the companys pre-profitability stage. Forecast: Cyclacel Pharmaceuticals (CYCC) is expected to remain under pressure in the next three months, with potential resistance at $0.35 (SMA50) and support at $0.30. The stock may trade sideways with limited upside due to its current technical setup and fundamental valuation metrics.